Search
Now showing items 1-5 of 5
Coverage and effect of intensive adherence counseling on viral load suppression in a public HIV Care Center, Kampala, Uganda: A mixed methods retrospective study January 2015 to October 2018
(Makerere University, 2022-02)
Background: Intensive adherence counseling (IAC) is fundamental to enhance adherence and increase durability of ART regimens among ART treated unsuppressed people living with HIV (PLWH). This study evaluated coverage, ...
Simulation of clonal expansion and latent HIV reservoir size prediction using machine learning in virally suppressed individuals in Uganda
(Makerere University, 2022-07)
Background: HIV can survive as pro-viruses that do not undergo transcription mostly within resting memory CD4+ T cells despite prolonged antiretroviral therapy (ART). This Latent Viral Reservoir (LVR) has an extremely long ...
Isoniazid preventive therapy completion and factors associated with non-completion among patients on antiretroviral therapy at Kisenyi Health Centre IV, Kampala, Uganda
(Makerere University, 2022-08)
Introduction: Isoniazid preventive therapy is given to people living with HIV to reduce the risk of active tuberculosis. However, treatment completion remains sub-optimal among those that are initiated. This study aimed ...
Low-level viraemia: An emerging concern among people living with HIV in Uganda and across sub-Saharan Africa
(AOSIS, 2022)
Attaining viral load (VL) suppression for over 95% of the people living with HIV on antiretroviral therapy is a fundamental step in enabling Uganda and other sub-Saharan African countries to achieve global Sustainable ...
Dual contraceptive utilization and associated factors among women living with the Human Immunodeficiency Virus (HIV) at Kawempe National Referral Hospital, Kampala Uganda
(Makerere University, 2022-12)
Introduction: Dual contraceptive utilization (DCU) maximizes the prevention of unintended pregnancies and sexually transmitted infections including HIV infection. In Uganda DCU among women living with HIV (WLHIV) is low. ...